新西兰从2026年5月开始资助新的CLL治疗. New Zealand funds new CLL treatments starting May 2026.

从2026年5月1日开始,新西兰将资助两种新的慢性淋巴细胞白血病 (CLL) 组合疗法. Starting May 1, 2026, New Zealand will fund two new combination therapies for chronic lymphocytic leukemia (CLL). 患者将获得与易布鲁替尼或奥比努祖马布结合的venetoclax作为第一线治疗,以及以易布魯替尼为第二线选择. Patients will gain access to venetoclax combined with ibrutinib or obinutuzumab as first-line treatments, along with ibrutinib as a second-line option. 根据患者反,这些变化旨在减少医院访问并改善治疗的可用性. These changes, following patient feedback, aim to reduce hospital visits and improve treatment accessibility.